MARINUS PHARMACEUTICALS INC's ticker is and the CUSIP is 56854Q200. A total of 85 filers reported holding MARINUS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $379,534 | -64.6% | 47,147 | -52.3% | 0.00% | – |
| Q2 2023 | $1,072,654 | +27.5% | 98,771 | -19.0% | 0.00% | – |
| Q1 2023 | $841,227 | +108.7% | 121,917 | +20.4% | 0.00% | – |
| Q4 2022 | $403,020 | +77.5% | 101,261 | +194.9% | 0.00% | – |
| Q3 2022 | $227,000 | -55.6% | 34,336 | -67.6% | 0.00% | – |
| Q2 2022 | $511,000 | +146.9% | 105,947 | +380.7% | 0.00% | – |
| Q1 2022 | $207,000 | -54.3% | 22,041 | -42.2% | 0.00% | – |
| Q4 2021 | $453,000 | +72.2% | 38,158 | +64.4% | 0.00% | – |
| Q3 2021 | $263,000 | -82.6% | 23,217 | -72.4% | 0.00% | – |
| Q2 2021 | $1,509,000 | +42.1% | 84,161 | +22.7% | 0.00% | – |
| Q1 2021 | $1,062,000 | +154.7% | 68,568 | +100.3% | 0.00% | – |
| Q4 2020 | $417,000 | +102.4% | 34,225 | +112.9% | 0.00% | – |
| Q3 2020 | $206,000 | – | 16,072 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lion Point Capital, LP | 2,145,337 | $17,269,963 | 7.70% |
| Bleichroeder LP | 1,872,463 | $15,073,327 | 3.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 5,204,942 | $41,899,783 | 2.26% |
| Opaleye Management Inc. | 584,000 | $4,701,200 | 1.53% |
| Bain Capital Life Sciences Investors, LLC | 1,431,058 | $11,520,017 | 1.29% |
| Cormorant Asset Management, LP | 2,625,000 | $21,131,250 | 1.23% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 290,000 | $2,337,400 | 0.79% |
| Ikarian Capital, LLC | 746,069 | $6,005,856 | 0.72% |
| Eventide Asset Management | 4,529,997 | $36,466,476 | 0.66% |
| Altium Capital Management LP | 125,033 | $1,006,516 | 0.52% |